Testing The Validity Of A Prognostic Model For Castration-Resistant Prostate Cancer

Testing the Validity of a Prognostic Model for Castration-Resistant Prostate Cancer

Castration Resistant Prostate Cancer: Diagnosis & Testing Considerations With Use of PARP Inhibitors

ASCP

Castrate resistant prostate cancer

The Prostate Coach

Prognostic Biomarker Tests for Prostate Cancer

Prognostic Factors in Prostate Cancer: Gleason Scores, PSA Levels, and Genomic Testing

GU Oncology Now

Dr. Crawford on Prognostic and Predictive Tests in Prostate Cancer

PROPHECY trial: AR-V7 CTCs as a biomarker in mCRPC

AR Resistance Mechanisms Focusing on Variants and Testing

Grand Rounds in Urology

Dr. Gafita on Prognostic Models for Treatment With 177Lu-PSMA-617 in mCRPC

Updates in the treatment of castration-resistant prostate cancer

Castration Resistant #ProstateCancer | #MarkScholzMD #PCRI

Prostate Cancer Research Institute

CTC enumeration as a prognostic biomarker in prostate cancer

Update on Mechanisms of Resistance in Castration-Resistant Prostate Cancer

Grand Rounds in Urology

Quantitative 68Ga-PSMA-11 PET and Outcomes in Metastatic Castration-resistant Prostate Cancer fol...

Impressions of a Patient With Progression to mCRPC

Targeted Oncology

BMI and clinical outcomes in patients with metastatic castration-resistant prostate cancer

Prostate Cancer: Validation of AR-V7 Testing

Improving the Prognosis for Patients With mCRPC

Targeted Oncology

AR V7 Predicts Response in CRPC

Grand Rounds in Urology

Dr. Sehdev, Medical Oncologist: What is mCRPC and what is the prognosis?

Prostate Cancer Matters